$5.1M in UTHR Stock Sold by CEO Martine Rothblatt Days After Phase III Trial Results — A Billion-Dollar Seller Trims Again

Martine Rothblatt, Chairperson and CEO of United Therapeutics Corporation (NASDAQ: UTHR), sold approximately $5.1 million in company stock across two trading days — March 12 and March 16, 2026. The sales came just days after the company discussed ADVANCE OUTCOMES Phase III clinical trial results on March 2 and presented at the Leerink Global Healthcare Conference on March 9. With these transactions, Rothblatt's career insider sales now exceed $1.05 billion.

Transaction Breakdown

The March sales involved an option exercise followed by multiple open-market dispositions at prices ranging from $534 to $544 per share:

Date	Type	Shares	Price	Value
2026-03-16	Sale	516	$534.99	$276,065
2026-03-12	Exercise	9,500	$146.03	$1,387,285
2026-03-12	Sale	164	$544.58	$89,311
2026-03-12	Sale	356	$543.22	$193,386
2026-03-12	Sale	600	$542.33	$325,398
2026-03-12	Sale	400	$541.31	$216,524
2026-03-12	Sale	1,240	$539.82	$669,377
2026-03-12	Sale	720	$538.94	$388,037

On March 12, Rothblatt exercised 9,500 options at $146.03 per share and immediately sold 3,480 shares at prices between $538.94 and $544.58 — a classic exercise-and-sell pattern. Four days later, she sold an additional 516 shares at $534.99. The combined sale proceeds totaled roughly $5.1 million, net of the exercise cost.

Why Now? Phase III Momentum and Conference Season

The timing of these sales aligns with a period of heightened visibility for UTHR:

• March 2, 2026 — United Therapeutics discussed results from the ADVANCE OUTCOMES Phase III clinical trial, a key catalyst for the company's pulmonary arterial hypertension (PAH) franchise.
• March 9, 2026 — Rothblatt presented at the Leerink Global Healthcare Conference, outlining the company's growth trajectory and pipeline progress.
• Revenue momentum — The company reported over $3 billion in revenue for 2025, driven by continued Tyvaso growth, and management has targeted a $4 billion revenue run rate by 2027.

Selling shortly after major corporate events is not unusual for systematic insiders — the sales likely occurred within a pre-planned trading window following the company's quiet period.

The Career Pattern: $1.05 Billion in Sales — But Not an Exit

With 6,319 career transactions on file, Martine Rothblatt is one of the most prolific insider sellers tracked on 13F Insight. Her cumulative sell volume of $1.05 billion dwarfs her $15.1 million in career purchases — a ratio that might alarm casual observers.

But context matters. According to an SC 13G/A filing dated February 14, 2024, Rothblatt holds 7.8% beneficial ownership in United Therapeutics. This includes shares held directly and through affiliated entities. The 8,414 shares reported on her latest Form 4 represent only her direct holdings — not her full economic stake in the company.

This is the profile of a systematic seller who remains deeply invested. Rothblatt has been trimming her position for years through regular option exercises and sales, a pattern consistent with diversification rather than a loss of conviction. Her beneficial ownership percentage — nearly 8% of a company with a market cap exceeding $15 billion — represents a stake worth well over a billion dollars.

Key Facts

Metric	Value
Career transactions	6,319
Career sell volume	$1.05 billion
Career buy volume	$15.1 million
Direct shares (Form 4)	8,414
Beneficial ownership (13G)	7.8%
Role	Chairperson & CEO

What to Watch

For investors tracking UTHR, several catalysts remain on the horizon:

• ADVANCE OUTCOMES data readouts — Full Phase III results and potential regulatory submissions for expanded PAH indications.
• Tresmi and super prostacyclin pipeline — Next-generation therapies that could extend United Therapeutics' PAH franchise beyond Tyvaso.
• IPF program progress — The idiopathic pulmonary fibrosis pipeline represents a significant TAM expansion opportunity.
• $4 billion revenue target — Management's 2027 revenue run-rate goal will be a key benchmark in upcoming quarterly reports.
• Continued insider selling cadence — Whether Rothblatt maintains her systematic selling pattern or pauses could signal shifting confidence levels.

Major institutional holders including Vanguard Group and Capital World Investors have maintained significant positions in UTHR, providing institutional backing alongside the CEO's ongoing — if gradually reduced — stake.